Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
130 Leser
Artikel bewerten:
(0)

Aviir, Inc.'s CEO Dr. Douglas Harrington Delivered The Facts Surrounding Heart Disease At The Los Angeles Ultimate Women's Expo

IRVINE, Calif., Nov. 4, 2012 /PRNewswire/ --Dr. Douglas Harrington, CEO of Aviir, Inc., joined a host of influential companies and experts at the Los Angeles Ultimate Women's Expo on Saturday, October 27 to discuss America's leading threat to women: Heart Disease. Dr. Harrington's lecture "Everything You Ever Wanted to Know About Heart Disease But Were Afraid to Ask" provided a higher level of insight into the disease and how women can empower themselves, improving their cardiovascular health. The speaking session began at 12:30 PM, at the Los Angeles Convention Center and was sponsored by GuardaHeart Foundation.

(Photo: http://photos.prnewswire.com/prnh/20121104/LA05795 )

As CEO of Aviir, Inc., Dr. Harrington brings more than 25 years of experience in the commercialization of health care technology. Aviir, Inc. is an Irvine-based biotechnology company that develops innovative diagnostic and laboratory tests. Dr. Harrington's personal mission is to offer clarity to heart disease through reliable assessments and prevention.

The Los Angeles Ultimate Women's Expo sought out some of the best seminar speakers around the world to participate in their event, which is held in several cities across the country.

GuardaHeart sponsors heart risk assessments through an on-going collaboration with Aviir. Far too many lives continue to be needlessly lost to heart disease, while many more are burdened with the medical debt caused by surviving a heart attack.

"Heart Disease remains the leading cause of death in the US, claiming almost 600,000 lives each year, yet many are unaware that 80% of heart disease is preventable through lifestyle modification," said Dr. Harrington. Through GuardaHeart's movement "Pledge to SaveThe1" individuals are empowered and equipped to make these critical lifestyle modifications.

Dr. Harrington also discussed an innovative blood test, developed through an Aviir/Stanford University cardiology collaboration, which identifies an individuals' cardiac risk in a five-year timeframe. "This timeframe allows preventive measures to be implemented," continued Dr. Harrington. "Our mission is to improve healthcare and encourage timely preventive strategies by providing this unique medical information."

About Aviir, Inc.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event. Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders - including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

About Los Angeles Ultimate Women's Expo
TheUltimateWomen's Expo unites thousands ofwomenwith the most respected companies and brands that provide valuable products and services designed to enrich the lives ofwomen. Indulge with the very best Los Angeles has to offer in shopping, fashion, food, entertainment, cosmetics, health and wellness and travel. Expo hours are October 27 and 28 from 10:00 AM. For more information, visit: http://www.lawomensexpo.com.

For media inquiries, please contact: Dina Scaglione (949) 398-6320 dina.scaglione@aviir.com

For Interviews at the Expo please contact:
Yvette Morales
YM & Associates
PR | Marketing | Branding | Business Development
California | New York
949.244.9769 | 310.499.0906 Fax
YMoralesY@YM-PR.com
YM-PR.com
Twitter: @YMTheBevHillsPR

SOURCE Aviir, Inc.

© 2012 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.